Vital Therapies Inc., a private, San Diego-based company developing a device to help people suffering from serious liver disease, said Sept. 12 that it has obtained $28.1 million in Series C financing.
The capital will go toward continued development of the Extracorporeal Liver Assist Device , the world’s only human cell-based artificial liver. The new financing was led by Versant Ventures, Delphi Ventures, HBM BioMed China and DFJ DragonFund China.
, Andrew Schweizer
